The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence
Open Access
- 17 December 2024
- journal article
- review article
- Published by MDPI AG in Antibiotics
- Vol. 13 (12) , 1223
Abstract
Rifampin is a crucial antibiotic in the management of prosthetic joint infections (PJI), particularly due to its effectiveness against staphylococcal bacteria and its ability to penetrate and disrupt biofilms. This review evaluates rifampin’s role by examining its mechanism of action, clinical efficacy, and integration into treatment regimens based on recent evidence and guidelines. Rifampin’s synergistic effects with other antibiotics, such as β-lactams and vancomycin, enhance bacterial eradication, and some evidence shows that it improves patient outcomes. However, evidence supporting its use is limited by the scarcity of robust human clinical trials, and challenges such as potential drug interactions and resistance development necessitate careful management. Ongoing research is needed to refine its use and address existing limitations in clinical practice.Keywords
This publication has 67 references indexed in Scilit:
- Pharmacokinetic interaction between rifampicin and clindamycin in staphylococcal osteoarticular infectionsInternational Journal of Antimicrobial Agents, 2023
- The Use of Rifampin in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis of Comparative StudiesThe Journal of Arthroplasty, 2022
- Factors affecting outcome in the treatment of streptococcal periprosthetic joint infections: results from a single-centre retrospective cohort studyInternational Orthopaedics, 2020
- Antibiotic penetration into bone and joints: An updated reviewInternational Journal of Infectious Diseases, 2019
- Influence of daily dosage and frequency of administration of rifampicin–levofloxacin therapy on tolerance and effectiveness in 154 patients treated for prosthetic joint infectionsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2015
- Pharmacokinetic variability of clindamycin and influence of rifampicin on clindamycin concentration in patients with bone and joint infectionsInfection, 2015
- Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection modelInternational Journal of Antimicrobial Agents, 2013
- Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitisInternational Journal of Antimicrobial Agents, 2010
- Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retentionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2010
- Role of Rifampin for Treatment of Orthopedic Implant–Related Staphylococcal Infections A Randomized Controlled TrialJAMA, 1998